CD274 and familial pancreatic carcinoma: In addition, a unique bispecific nanobody against the immune system suppressing molecules PD-L1 and CXCR4 was superior in inhibiting tumour growth compared with anti-PD-L1 mAb in pancreatic cancer xenografted mice model 37.